Skip to main content
. Author manuscript; available in PMC: 2017 Oct 12.
Published in final edited form as: Ann Surg Oncol. 2016 Feb 4;23(6):1993–2000. doi: 10.1245/s10434-016-5116-4

FIG. 4.

FIG. 4

Preclinical trial of gemcitabine followed by trametinib for occult metastatic PDAC. Adjuvant gemcitabine followed sequentially by daily trametinib therapy resulted in significantly increased time to proliferative outgrowth and decreased metastatic tumor burden at conclusion of the trial in the livers of mice harboring Tumor 608 (a, p = 0.0262) and Tumor 366 (b, p = 0.0007) compared with vehicle control or gemcitabine alone. This adjuvant regimen resulted in increased 35-day PFS (p = 0.0108) in Tumor 608 (c) and improved median PFS (p = 0.0367) and 100-day PFS (p = 0.007) in tumor 366 (d)